Journal
NEUROLOGY
Volume 79, Issue 10, Pages 1027-1032Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3182684646
Keywords
-
Categories
Funding
- Tel Aviv Sourasky Medical Center Grant of Excellence
- Khan Foundation
- Israel Science Foundation Heritage Legacy
- Michael J. Fox Foundation for Parkinson's Research
- UMC ST Radboud, Nijmegen, the Netherlands
- Michael J. Fox Foundation, New York, New York
- National Parkinson Foundation
- Solvay Pharmaceuticals
- TEVA
- RAFA
- Medtronic
- Novartis
- Medison
- Allergan
- GlaxoSmithKline
- Perrigo
- Intec Pharma
- Israeli Science Foundation Legacy Heritage Fund
- Chief Scientist Department of Health, Israel
- ALS Association USA
- Kahn Foundation Israel
- Columbia University from Neurosearch, NeuroSearch Sweden AB
- Medivation
- MJFF
- Huntington Disease Society of America
- Parkinson Study Group
- CHDI
- Teva-Lundbeck
- UCB
- NeuroDerm
- Schwartz Pharma
- Merz
- NPF
- Israeli Science Foundation
- NIH
Ask authors/readers for more resources
Objective: To assess cognitive abilities of healthy first-degree relatives of Ashkenazi patients with Parkinson disease (PD), carriers of the G2019S mutation in the LRRK2 gene. Methods: In this observational study, 60 consecutive healthy first-degree relatives (aged 50.9 +/- 6.2 years; 48% male; 30 G2019S carriers) were assessed using a computerized cognitive program, the Montreal Cognitive Assessment questionnaire, the Unified Parkinson's Disease Rating Scale Part III, and the Geriatric Depression Scale. Results: G2019S carriers scored significantly lower on the computerized executive function index (p = 0.04) and on specific executive function tasks (Stroop test, p = 0.007). Conclusion: Carrying the LRRK2 G2019S mutation was associated with lower executive performance in a population at risk for PD. Neurology (R) 2012;79:1027-1032
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
